Registry-listed formulations

metadoxine · mesh:C037845

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 3 studies. This list may not include all unresolved or historical entries.

  • Extended Release MetadoxineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Metadoxine extended releaseRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • metadoxineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Phase 4
1
17%
Phase 3
1
17%
Phase 1
1
17%
Phase 2
3
50%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
Phase 41 (16.7%)

Trials by Status

unknown117%
withdrawn117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
withdrawnphase_3

Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis

NCT02541045
unknownphase_4

Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis

NCT02051842
completedphase_1

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

NCT00995085
completedphase_2

A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease

NCT01504295
completedphase_2

Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

NCT02019056
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02541045Phase 3

Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis

Withdrawn
NCT02051842Phase 4

Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis

Unknown
NCT00995085Phase 1

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Completed
NCT01504295Phase 2

A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease

Completed
NCT02019056Phase 2

Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

Completed
NCT02189772Phase 2

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
6

Names & Codes

Trade Names

MetadoxilMetadoxyl